Latest PD-1 Stories
Studies Find Potentially Predictive Biomarkers May Lead to Better Patient Outcomes, Bladder Cancer Treatment Options Extend Beyond Chemotherapy Milwaukee, WI
immunoSEQ(TM) Next Generation Sequencing Assay Confirms Presence of Active Immune Response in Responders Prior to Treatment SEATTLE, Nov.
SAN DIEGO and BARCELONA, Spain, Nov.
Results Published in Cancer Epidemiology, Biomarkers & Prevention Demonstrate Utility of Caris Molecular Intelligence(TM) in Exploring Expression of Targetable Immune Proteins IRVING,
The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept.
Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources
NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system.
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma.
Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES,
- totally perplexed and mixed up.